Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 156 Lung Neoplasms 57 Uterine Cervical Neoplasms 53 Squamous Cell Carcinoma of Head and Neck 52 Nasopharyngeal Carcinoma 51 Head and Neck Neoplasms 47 Stomach Neoplasms 37 Parkinson Disease 4, Autosomal Dominant Lewy Body 35 Esophageal Neoplasms 31 Urinary Bladder Neoplasms 26 Small Cell Lung Carcinoma 21 Esophageal Squamous Cell Carcinoma 21 Ovarian Neoplasms 19 Carcinoma 14 Neoplasm Metastasis 13 Cholangiocarcinoma 13 Recurrence 11 Neuroblastoma 11 Nasopharyngeal Neoplasms 11 Carcinoma, Ovarian Epithelial 11 Biliary Tract Neoplasms 11 Adenocarcinoma Of Esophagus 11 Neoplasms 10 Gallbladder Neoplasms 10 Carcinoma, Transitional Cell 10 Testicular Neoplasms 9 Adenocarcinoma of Lung 9 Teratoma 8 Oropharyngeal Neoplasms 8 Endometrial Neoplasms 8

Interventions

Gemcitabine 2 pembrolizumab 1 Vinorelbine 1 Erlotinib Hydrochloride 1 Docetaxel 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Advanced Non-Small Cell Lung Cancer × Cisplatin × Clear all

NCT00349219 2016-01-15

TORCH

National Cancer Institute, Naples

Phase 3 Completed

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡